BioCentury
ARTICLE | Product Development

WHO data show quartet of therapies fail to reduce COVID death

Gilead’s Veklury among repurposed therapies missing mark in SOLIDARITY

October 16, 2020 12:44 AM UTC
Updated on Oct 20, 2020 at 7:13 PM UTC

Data from WHO’s SOLIDARITY trial reiterate the results of NIH’s ACTT: Veklury does not provide a survival benefit in COVID-19.

The interim results from WHO’s open-label master protocol trial, published Thursday in medRxiv, showed that Veklury remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) failed to reduce 28-day mortality in hospitalized COVID-19 patients, missing the primary endpoint...